What You Need To Know Before the Medicare GLP-1 Bridge Goes Live

Starting July 1, Medicare will cover select glucagon-like peptide-1 (GLP-1) receptor agonists for obesity for the first time in the program's history at a flat $50 monthly co-pay through an 18-month demonstration.¹ This Medicare GLP-1 Bridge program now stands as the only pathway to access for this population after the longer-term BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive Health) Model, which was supposed to launch in January 2027 following the Bridge program, was shelved indefinitely by CMS in April 2026.

The Bridge, originally designed as a 6-month stopgap, was quietly extended through December 31, 2027, after major insurers declined to commit to BALANCE, citing financial uncertainty and insufficient utilization data.² CMS cited the need for "further evaluation and data collection" and gave no timeline for revisiting Medicare implementation.³ This development fundamentally changed the stakes of the Bridge program and the questions clinicians, plans, and patients must now confront.

How the Medicare GLP-1 Bridge Works

The Bridge operates entirely outside the standard Part D benefit such that Part D sponsors bear no financial risk and need not opt in.⁴ Humana will serve as the central processor, managing prior authorization, claims adjudication, and pharmacy reimbursement.⁵ Pharmacies collect the $50 co-pay and bill Humana directly. Drug manufacturers have agreed to a negotiated net price of $245 per 30-day supply, with the difference between that and wholesale acquisition cost returned to CMS.

Only Wegovy (semaglutide; Novo Nordisk), Zepbound (tirzepatide; Eli Lilly), and Foundayo (orforglipron; Eli Lilly) qualify, and other GLP-1 formulations are not covered under the Bridge. Beneficiaries already receiving a GLP-1 through their Part D plan for a covered indication such as diabetes or cardiovascular risk reduction will continue on that benefit and do not transition to the Bridge.

Prescribers must submit prior authorization attesting that the patient meets 1 of 3 body mass index (BMI)–based eligibility tiers. These include (1) a BMI of 35 or higher with no additional requirement; (2) a BMI of 30 or higher with comorbid heart failure, uncontrolled hypertension, or chronic kidney disease; or (3) a BMI of 27 or higher with prediabetes, prior myocardial infarction, prior stroke, or peripheral artery disease. Relevant diagnoses and BMI measurements must be clearly documented in the chart before initiating the process, and full prior authorization guidance from CMS is expected in June.

Notably, the $50 co0pay does not count toward a beneficiary's Part D deductible or $2100 out-of-pocket maximum, and low-income subsidy cost-sharing protections do not apply. For the most financially vulnerable eligible beneficiaries, the flat $50 monthly cost may be prohibitive.

What Clinicians and Patients Need to Know

For clinicians treating obesity, the Bridge represents something genuinely new and long overdue. "It sounds quite exciting for Medicare beneficiaries," said Fatima Cody Stanford, MD, MPH, MPA, associate professor of medicine and pediatrics at Harvard Medical School and obesity medicine physician scientist at Massachusetts General Hospital's Endocrine Division. "We haven't really seen any programs on the federal level for Medicare beneficiaries with obesity. We know that semaglutide and tirzepatide are both highly effective medications for the treatment of obesity, and we have a lot of robust data from both the SELECT and SURMOUNT trials for these patient populations. I'm really excited to see how this pilot works, and maybe it will be a potential solution that we can use for the 65-plus population."

Stanford noted that GLP-1 loss at Medicare eligibility had become a defining fear for patients approaching age 65. "Up until now, all of my patients that are about to hit 65 are terrified to hit 65—not because they're getting older, but they know they're going to lose their employer-sponsored insurance coverage if they switch to Medicare, and they'll lose coverage for Wegovy and Zepbound, unless they have a really great savings."

Yet the BALANCE programs shelving casts a shadow over that relief. Stanford raised a concern now more pressing than when BALANCE still appeared viable: "Will they continue this after the [18] months, or will patients just get short-term benefit, but it then not be something that they're able to sustain?" She drew a pointed comparison to how other chronic conditions are managed, in that this sort of temporary coverage that is then pulled back would not happen for diseases other than obesity. "It’s like: here’s a little appetizer, but you don't get the main course," she said.

What Health Plans and the Market Need to Know

The immediate operational burden for plans remains minimal as the Bridge runs outside their benefit and they bear no cost for it. But the BALANCE delay has market implications that extend well beyond Medicare.

"Normally, when Medicare picks up something, the industry has to pick it up as well, and it filters through," said Tim Church, MD, MPH, PhD, chief medical officer at Wondr Health. Church also flagged the pricing signal embedded in the program: "We've now set a bar for a price point of $50 a month." With GLP-1 injectables already inexpensive to manufacture and oral formulations even more so, "these developments all point towards competition and price pressure," he said.

The insurance industry, meanwhile, frames the Bridge extension as a reasonable outcome. "The Bridge model is a common-sense step to maintain access for seniors and generate important learnings that can be applied to ensure sustainable coverage moving forward," said Chris Bond, a spokesman for AHIP. The organization added that the extension provides "an essential foundation for the development of actuarially sound bids and accompanying actuarial certifications that meet Part D bid submission standards," and noted that it would "continue to monitor the results of the Bridge model."

AHIP also pointed to manufacturer pricing as a lever worth pulling: "GLP-1 manufacturers have agreed to significant discounts for those paying cash for their GLP-1 medications, and to make lower prices available to Medicaid and Part D enrollees. They should make those savings available to those with commercial insurance."

What We Still Don't Know

When, or whether, BALANCE returns to Medicare remains an important question, and CMS has given no concrete timeline. The utilization data that CMS intends to collect through the Bridge is one input, but whether that data are sufficient to bring major insurers back to the table is another question entirely.

What happens after December 2027 is another unanswered question. The Bridge now runs 18 months, rather than the originally intended 6, but it remains a demonstration with no statutory backing, and congressional action would be required to make obesity drug coverage permanent in Medicare. Importantly, the underlying statutory prohibition on Medicare covering weight-loss drugs has not been lifted. If Congress has not acted by the time the Bridge expires, patients who have been on these medications for a year and a half face an abrupt coverage cliff.

Expanded GLP-1 utilization is projected to cost up to $47.7 billion under a Medicare coverage model, according to Huron research.² Whether CMS can structure a Medicare model that satisfies the Center for Medicare and Medicaid Innovation's budget-neutrality requirement while also being actuarially credible enough for large plan sponsors to commit remains the central unsolved problem in this space.

The Medicare GLP-1 Bridge's July 1 launch is now the only concrete milestone on the calendar. Whether it becomes the foundation for durable Medicare obesity coverage or simply an 18-month pause before another policy gap remains to be seen.

References

1. Freed M, Cubanski J, Williams E. What to know about the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge. KFF. March 24, 2026. Accessed April 14, 2026. https://www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid/
2. CMS delays Part D portion of BALANCE ,odel on expansion of GLP-1 access. AHA News. April 22, 2026. Accessed June 1, 2026. https://www.aha.org/news/headline/2026-04-22-cms-delays-part-d-portion-balance-model-expansion-glp-1-access
3. LaPointe J. CMS benches BALANCE Model for Medicare. TechTarget Healthcare Payers. April 23, 2026. Accessed June 1, 2026. https://www.techtarget.com/healthcarepayers/news/366642140/CMS-benches-BALANCE-Model-for-Medicare
4. Medicare GLP-1 Bridge. CMS. Accessed June 1, 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
5. CMS announces changes to Medicare coverage of GLP-1 medications for 2027. Obesity Medicine Association. May 17, 2026. Accessed June 1, 2026. https://obesitymedicine.org/blog/cms-announces-changes-to-medicare-coverage-of-glp-1-medications-for-2027/